Drug General Information |
Drug ID |
D0Q5NX
|
Former ID |
DAP001255
|
Drug Name |
Lenalidomide
|
Synonyms |
Revamid; Revimid; Revlimid; Celgene brand of lenalidomide; Lenalidomide [USAN]; CC 5013; CC5013; CDC 501; IMiD3; IMiD3cpd; ALBB-015321; CC-5013; CDC-501; CDC-5013; ENMD-0997; IMID-5013; Revlimid (Celgene); Revlimid (TN); Thalidomide analog CC-5013; Lenalidomide (USAN/INN); CC-5013, Revlimid, Lenalidomide; 3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione; 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(7-Amino-3-oxo-1H-isoindol-2-yl)-piperidine-2,6-dione; 3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione; Lenalidomide (Immunomodulator)
|
Drug Type |
Small molecular drug
|
Therapeutic Class |
Anticancer Agents
|
Company |
Celgene Corporation
|
Structure |
|
Download
2D MOL
3D MOL
|
Formula |
C13H13N3O3
|
InChI |
InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)
|
InChIKey |
GOTYRUGSSMKFNF-UHFFFAOYSA-N
|
CAS Number |
CAS 191732-72-6
|
PubChem Compound ID |
|
PubChem Substance ID |
9372858, 12015317, 14847985, 30420059, 46505725, 47206522, 50067858, 50112744, 50484855, 53786789, 57399776, 81092908, 85174578, 91148448, 92719197, 99437218, 103222228, 109693476, 113461419, 117883377, 119509589, 124409664, 124756946, 124893327, 124893328, 125163752, 125343917, 126591352, 126628313, 126652519, 126667069, 127984536, 134338492, 134964412, 135134887, 135600354, 135610831, 135683667, 136367898, 136374703, 136949134, 137000301, 137039885, 140119412, 143496160, 144116136, 144206045, 152237735, 152258939, 160647784
|
SuperDrug ATC ID |
L04AX04
|
Drug Resistance Mutation (DRM) |
Target and Pathway |
References |